Should gender transition treatments be illegal for minors under 18?

The 2024 Cass Review found weak evidence for the safety and effectiveness of puberty blockers and cross-sex hormones for gender-dysphoric youth, citing risks to bone density and unknown long-term effects. NHS England halted routine prescribing of puberty blockers outside trials and now plans to stop cross-sex hormones for under-18s, with private provision also restricted. Around 9,000 former Tavistock patients lack comprehensive long-term follow-up data due to adult clinics' refusal to share records.